Semaglutide dose increases: how to tell when the time is right

Four weeks in, and nothing dramatic has happened yet

This is the situation most people find themselves in. You've injected 0.25 mg once a week for a month, you haven't felt terrible, but you haven't lost a dramatic amount of weight either. It feels like nothing is happening. That's normal, and it's deliberate. The 0.25 mg starting dose exists to give your digestive system time to adapt to the medicine, it's a tolerability phase, not a therapeutic one. The weight-management effect builds as the dose rises.

Before you think about moving up, run through a quick check that takes less than a minute: look back at the last two to three injections and ask honestly whether you've had significant nausea, vomiting or stomach pain in the 48 hours after each one. If the answer is yes, and those symptoms haven't settled, moving up is likely to make things worse. If the answer is no, or the side effects were mild and faded quickly, you and your prescriber are probably in the right window to consider the next step.

The NHS patient information for semaglutide notes that the usual escalation pathway moves from 0.25 mg to 0.5 mg, then 1.0 mg, 1.7 mg and finally 2.4 mg, with roughly four weeks at each level, and if you're curious about where Wegovy 0.05 mg fits into that picture, that page explains its specific role. Your prescriber follows this schedule, adjusted to how you're doing. For a broader look at how Wegovy fits into a weight-management plan, the Wegovy overview covers the full picture.

When a dose increase is clinically appropriate, and when it isn't

A dose increase is generally appropriate when you've completed at least four weeks at your current dose, side effects have settled to a manageable level, and your prescriber has reviewed your progress. It's worth knowing that "settled" doesn't have to mean zero side effects, mild, brief nausea after an injection that clears within a day or two is common and doesn't usually prevent titration. Persistent or severe nausea, vomiting that's affecting your ability to eat or stay hydrated, or stomach pain that lingers for several days are all reasons to stay where you are a little longer.

There are situations where the evidence supports slowing the schedule rather than sticking rigidly to four-week steps. If you had a difficult few weeks at a particular dose (a stomach bug, a stressful period, a change in your eating pattern) your body's response to the medicine may look different than it would under normal conditions. Your prescriber will take that into account. Rushing the titration to reach the maintenance dose faster rarely produces better outcomes, and it reliably produces more side effects.

For a detailed walkthrough of the practical side of moving between doses, the page on how to increase your semaglutide dose goes into the step-by-step process. If you're specifically using Wegovy and want guidance on the dose schedule, Wegovy doses explained sets out each stage clearly.

What happens if you stay at a lower dose for longer than planned

Life intervenes. Sometimes people stay at 0.5 mg or 1.0 mg for six or eight weeks rather than four, because a side effect took longer to resolve, or because a clinical review was delayed. The evidence doesn't suggest this harms outcomes, in fact, the STEP 1 trial published in the New England Journal of Medicine, which studied semaglutide 2.4 mg in 1,961 adults with obesity over 68 weeks, found that the treatment's average weight reduction of around 15% was achieved on a gradual titration schedule. Nobody was rushed.

What tends to matter more than tight adherence to four-week intervals is consistent use of the medicine and a sustainable relationship with each dose before moving on. If you've been at a dose for longer than planned and want to understand the right moment to step up, our page on semaglutide dosage increase walks through the key considerations before a prescriber review confirms the timing. The guidance on when to increase Wegovy dose is a useful companion read alongside this page.

One thing worth knowing: if you've reached the 2.4 mg maintenance dose and your progress has plateaued, the MHRA approved a dedicated 7.2 mg single-dose pen in April 2026, offering a higher maintenance option. Whether that's appropriate for you is a question for your prescriber, it isn't available to everyone, and eligibility is assessed individually. Details of what's currently available through a regulated service are on the treatment options page.

Why this is always a prescriber's call, not yours alone

It's easy to read a titration schedule and assume it's a simple countdown, four weeks pass, you go up. In practice, it's a clinical assessment. Your prescriber is looking at your reported side effects, your weight trajectory, any other medicines you take, and whether there are any flags that suggest a different approach. For tirzepatide and semaglutide alike, NHS England's guidance on weight-management injections is clear that dose changes should happen within a supported clinical relationship, not in isolation.

At nume, every dose review is read by a real prescriber before anything changes. If you started treatment elsewhere and want to move your care across, or if you're unsure whether your current dose is working as well as it should, our prescribers can review your situation properly. Treatment through a regulated service also means your progress is checked before each repeat, not just at the start. If you're ready to discuss your dosing with a clinician, starting a free consultation is the first step.